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ABSTRACT
Background. Long-term outcomes of the Eurotransplant Senior Program (ESP) are urgently needed to improve selection
criteria and allocation policies in the elderly.
Methods.We analysed patient and allograft outcomes of 244 ESP-kidney transplant recipients (KTRs) between 1999 and
2019 and assessed quality of living compared with 82 ESP-waitlisted dialysis patients using standardized short form-8.
Results.We observed 1-, 5- and 10-year patient survival of 91.7, 66.3 and 38.0%, respectively. Mortality risk factors included
male gender (P¼0.006) and T-cell-mediated rejection (P<0.001). Median patient survival of male ESP-KTRs was 80 versus
131months for female ESP-KTRs (P¼0.006). 1-, 5- and 10-year death-censored allograft survival was 93.3, 82.6 and 70.4%.
Risk factors included high body mass index (P<0.001) and T-cell-mediated rejection (P<0.001). After re-initiation of dialysis
median patient survival was 58months. Change of estimated glomerular filtration rate showed a mean decline of 2.3 and
6.8mL/min at 5 and 10 years. Median physical and mental component scores of ESP-KTRs were 40.2 and 48.3, significantly
higher compared with dialysis patients (P<0.05). Of ESP-KTRs, 97.5% who underwent transplantation would again do so.
Conclusions. Long-term outcomes of ESP-KTRs ultimately support the effectiveness of an age-matched allocation system.
Our data suggest that the survival advantage of women is maintained after kidney transplantation and calls for gender-
specific care.
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INTRODUCTION
To meet the needs of an ageing society and consider the in-
creasing scarceness of organs, the Eurotransplant Senior
Program (ESP) in conjunction with the Eurotransplant Kidney
Allocation System was newly established on 4 January 1999,
and performed in all Eurotransplant member countries (Austria,
Belgium, Croatia, Germany, Hungary, Luxembourg, the
Netherlands and Slovenia) [1, 2]. Organs from donors over the
age of 65 years are allocated to recipients over the age of
65 years. Through a regional allocation system and by circum-
venting human leukocyte antigen (HLA) matching, a short cold
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ischaemia time (CIT) should be achieved, all with the intention
to increase the number of elderly donors used for transplanta-
tion. So far, almost 10 000 ESP kidney transplant recipients (ESP-
KTRs) were transplanted within the last 20 years [3].
By generating a shorter waiting time for the elderly on the
transplant waiting list, previous reports suggest favourable
short-term patient and kidney allograft outcomes and increased
life expectancy of the ESP-KTR population [4–8]. Here, data from
the ERA-EDTA registry support the finding, which even among
ESP-KTRs life expectancy increases compared with those receiv-
ing dialysis, although the relative difference in the expected
remaining lifetime increases compared with the age-matched
general population [9].
Quite recently, the Dialysis Outcomes and Practice Pattern
Study suggested that the gender gap in mortality, the survival
advantage of women over men in the general population, is
markedly diminished among end-stage kidney disease patients
undergoing haemodialysis [10, 11]. Again, data from the ERA-
EDTA registry support this finding in a European cohort that the
gender gap in mortality almost disappeared among haemodial-
ysis and peritoneal dialysis patients [9]. Although causality for
the observed sex differences could not be provided by the study,
it is highly suggestive to attribute this finding to end-stage
kidney disease and dialysis therapy itself. Since most studies on
elderly KTRs are limited to short-term data of only 5 years post-
transplantation, any potential impact of kidney transplantation
on the gender gap in mortality has been neglected so far.
Therefore, long-term patient and kidney allograft outcomes of
the ESP are urgently needed to address the benefit for male and
female ESP-KTRs and to improve selection criteria, patient edu-
cation and allocation policies.
Here, we tried to address the following questions: (i) what
factors impact patient survival and death-censored allograft
survival among ESP-KTRs? (ii) what impact does the kidney
transplantation have on the gender gap in mortality? and (3)
what impact does kidney transplantation have on quality of life
compared with dialysis patients waitlisted within the ESP?
MATERIALS AND METHODS
Patients
This study was performed in compliance with the declaration of
Helsinki. Informed written consent was obtained from all
patients. We retrospectively examined 244 adult solitary KTRs
of a first kidney allograft transplanted within the ESP at our sin-
gle transplant centre at the Charité Campus Virchow Clinic be-
tween 1999 and 2019. Within the ESP kidneys from donors aged
65years are allocated to recipients aged 65years. To account
for minimization of CIT, kidneys are preferably allocated locally.
ESP allocation is performed by waiting time and blood group
only but not HLA matching. Registered KTRs 65years option-
ally enter the ESP at the age of 65 years by keeping their accu-
mulated waiting time [7].
In addition, 102 dialysis patients waitlisted within the ESP at
our centre at the Charité Campus Virchow Clinic were analysed.
Immunosuppressive therapy
Primary immunosuppression was a triple drug regimen with a
calcineurin inhibitor (tacrolimus or cyclosporine), mycopheno-
late mofetil (MMF) or mycophenolic acid and steroids tapered to
a maintenance dose of 4mg methylprednisolone after 4weeks.
All patients received induction with an IL-2R antagonist
(basiliximab or daclizumab), except presensitized KTRs.
Presensitized KTRs received a lymphocyte-depleting agent (mur-
omonab 3, anti-thymocyte globulin or alemtuzumab) for
induction.
Diagnosis and treatment of acute allograft rejection
If acute rejection was suspected, then a kidney biopsy was per-
formed and the rejection classified according to the current
Banff classifications. Borderline changes and T-cell-mediated
rejections Grades IA and IB were treated with intravenous ste-
roids for 3–5 days. T-cell-mediated rejections grade Banff IIA, IIB
or III were treated with a lymphocyte-depleting agent with/
without steroid pulses.
Data collection procedures, aftercare and follow-up
Data collection included demographic, socio-demographic and
medical characteristics. All data were obtained from the patient
records and clinic database.
At the time of data assessment, patient death or kidney allo-
graft loss, 153 KTRs (62.7%) were treated quarterly in our trans-
plant centre. Ninety-one KTRs (37.3%) were followed by local
nephrologists or general practitioners only. Data on KTRs who
were followed by local nephrologists only were provided by
those local nephrologists. Follow-up rates were high with a 1-,
5-, 10- and 15-year follow-up rate at the time of data analysis of
99.2, 97.9, 95.6 and 92.3%, respectively. Only 16 of 244 ESP-KTRs
(6.6%) were lost to follow-up at any time after transplantation.
Two ESP-KTRs were lost within 1year post-transplant, another
six ESP-KTRs were lost within 5years post-transplant, another
five ESP-KTRs were lost within 10years post-transplant and
three ESP-KTRs were lost after 15 years post-transplant. After
kidney allograft loss, ESP-KTRs were followed for death on dial-
ysis. At the time of data analysis, follow-up rate was 100%.
Questionnaire-based survey on health-related quality of
life
The German version of the internationally standardized short form-
8 (SF-8) questionnaire was used to evaluate health-related quality of
life. The SF-8 questionnaire was sent in July 2017 to all KTRs trans-
planted within the ESP who are alive with a functioning allograft. In
addition, the SF-8 questionnaire was sent to 102 patients on dialysis
waitlisted within the ESP. KTRs and dialysis patients returned the
completed questionnaire via a pre-stamped envelope. Non-
respondents were reminded by a second letter 4 weeks later and/or
contacted by phone. Response rate of KTRs within the ESP was
77.4% (72/93 ESP-KTRs). Response rate of dialysis patients waitlisted
within the ESPwas 81.4% (83/102 dialysis patients).
The SF-8 scores ranging from 0 (complete dissatisfaction) to
100 (full satisfaction) for eight domains: physical functioning,
role-physical, bodily pain, general health, vitality, social func-
tioning, role-emotional and mental health. The correlated phys-
ical component score (PCS) and mental component score (MCS)
were computed by the providers software.
In addition to the SF-8 questionnaire, all KTRs were
assessed, if they would again decide to undergo kidney
transplantation.
Statistical methods
Statistical tests were performed using SPSS Version 23 (SPSS,
Chicago, IL, USA). For comparisons of study groups, two-sided
Mann–Whitney U-test for non-parametric independent samples



































































was used. Clinical characteristics were compared across groups us-
ing Fisher’s exact test categorical variables. Outcomes were mea-
sured with Kaplan–Meier models and overall strata comparisons
measured by log-rank tests. Stepwise regression was performed to
select variables that approached statistical significance in the uni-
variate analysis. A P < 0.10 was used for selection. Multivariate Cox
regression was performed for selected variables. Box plots show
median and interquartile range. The whiskers are drawn down to
the 10th and up to the 90th percentile. Two-sided P < 0.05 were
considered statistical significant.
RESULTS
Clinical characteristics of ESP-KTRS
A total of 244 ESP-KTRs of a first kidney allograft were analysed.
Patient characteristics are shown in Table 1. Median follow-up of
ESP-KTRs was 48 months (range 0–189 months), during which 107
ESP-KTRs died (43.8%) and 44 returned to dialysis (18.0%). Remaining
93 ESP-KTRs with a functioning kidney allograft were assessed by
the questionnaire-based survey on health-related quality of life.
For comparison, quality of life of 102 dialysis patients wai-
tlisted within the ESP was analysed. Median age of dialysis
patients was 69years (range 65–81years), 68 of 102 (66.7%) were
males, median time on dialysis at the time of analysis was
49months (range 11–82months).
Patient and kidney allograft outcomes among ESP-KTRs
Patient survival. Among all ESP-KTRs, we observed 1-, 5- and
10-year patient survival of 91.7, 66.3 and 38.0%, respectively
(Figure 1A). Median patient survival of ESP-KTRs was 86months
(Figure 1A), and median age of death of ESP-KTRS was 74years
(range 65–86years). Upon multivariate analysis, male gender
was identified as the only independent mortality risk factor at
the time of transplantation [odds ratio (OR) ¼ 1.777, 95% confi-
dence interval (CI) 1.181–2.672; P¼ 0.006]. Median patient sur-
vival of male ESP-KTRs was 80months versus 131months for
female ESP-KTRs (Figure 1B). Median age of death of male ESP-
KTRS was 72 years (range 65–86 years) compared with female
ESP-KTRs with 76years (range 65–82 years). Donor–recipient
gender mismatch showed inferior patient survival for both
male and female KTRs. Differences, however, did not reach sta-
tistical significance (Figure 1C).
Using Cox regression with the time of T-cell-mediated rejec-
tion as the time-dependent covariate showed a significantly in-
ferior patient survival with a hazard ratio (HR) of 2.293 (95% CI
1.451–3.623; P¼ 0.001) among ESP-KTRs with T-cell-mediated re-
jection compared with ESP-KTRs without T-cell-mediated rejec-
tion. Upon univariate analysis, neither overall HLA-mismatch
nor HLA-DR mismatch was associated with patient survival
(Supplementary data, Table S1).
Kidney allograft survival. Among all ESP-KTRs, we observed
that 1-, 5- and 10-year death-censored allograft survival was
93.3, 82.6 and 70.4%, respectively (Figure 1D). Upon multivariate
analysis, high body mass index (BMI) was identified as the only
independent risk factor for allograft loss (OR ¼ 1.096, 95% CI
1.044–1.150; P< 0.001). No differences were observed for death-
censored kidney allograft survival between male and female
ESP-KTRs (P¼ 0.572; Figure 1E) or donor–recipient gender mis-
match (P¼ 0.346; Figure 1F). Using Cox regression with the time
of T-cell-mediated rejection as the time-dependent covariate
showed a significantly inferior death-censored kidney allograft
survival with an HR of 2.064 (95% CI 1.356–4.634; P¼ 0.019)
among ESP-KTRs with T-cell-mediated rejection compared with
ESP-KTRs without T-cell-mediated rejection.
Upon univariate analysis, neither overall HLA-mismatch nor
HLA-DR mismatch was associated with an increased risk of T-
cell-mediated rejection (P¼ 0.561; P¼ 0.736), nor inferior death-
censored kidney allograft survival (Supplementary data,
Table S2).
Twenty-eight of 244 ESP-KTRs (11.5%) developed donor-
specific antibodies (DSAs) after kidney transplantation. Median
time of first occurrence of DSA was 16months after kidney
transplantation (range 1–117months). No ESP-KTR showed kid-
ney allograft loss due to antibody-mediated rejection in further
follow-up.
Overall, uncensored kidney allograft survival among all ESP-
KTRs was 85.5, 54.7 and 26.7% at 1-, 5- and 10-years, respectively
(Figure 1G). Median uncensored kidney allograft survival of
male ESP-KTRs was 60months versus 81months for female
ESP-KTRs (0¼ 0.055; Figure 1H).
Kidney allograft function. Nine of 244 ESP-KTRs (4%) showed
primary non-function and 110 of 244 ESP-KTRs (45%) showed
delayed graft function (DGF). Male ESP-KTRs were more likely to
show DGF compared with female ESP-KTRs (P¼ 0.017; Table 1).
Upon univariate analysis, two HLA-DR mismatch was not asso-
ciated with an increased risk of DGF (P¼ 0.090). However, two
HLA-DR mismatch among male ESP-KTRs was associated with
an increased risk of DGF with an HR of 1.675 (95% CI 1.018–2.756;
P¼ 0.042).
Median estimated glomerular filtration rate (eGFR) of all ESP-
KTRs at 12months post-transplantation was 39.7mL/min (range
13.6–87.0mL/min). The mean annual decline in eGFR indepen-
dent from kidney allograft loss was 0.4mL/min. Change of eGFR
showed a mean decline of 2.3 and 6.8mL/min at 5- and 10-years
post-transplantation (Figure 2A). Median eGFR of male ESP-
KTRs was 38.7mL/min range (range 13.6–87.0mL/min) com-
pared with 41.7mL/min (range 15.9–79.2mL/min) among female
ESP-KTRs (P¼ 0.868). No differences were observed with respect
to the decline of eGFR between male and female ESP-KTRs
(Figure 2B). No differences were observed for median eGFR and
decline of eGFR at any time post-transplantation with respect to
donor–recipient gender mismatch (P> 0.05).
Patient survival after kidney allograft loss. Among ESP-KTRs
who showed kidney allograft loss, median patient survival after
re-initiation of dialysis treatment was 58months (range: 0–
152months; Figure 3A). ESP-KTRs with kidney allograft loss
<12months after transplantation showed a median patient sur-
vival of 40months compared with 82months among ESP-KTRs
with kidney allograft loss >12months after transplantation
(P¼ 0.020; Figure 3B). No differences were observed for patient
survival after kidney allograft loss between male and female
ESP-KTRs (P¼ 0.583; Figure 3B). None of those ESP-KTR with kid-
ney allograft loss underwent retransplantation.
Quality of life of ESP-KTRs compared with waitlisted di-
alysis patients
PCS of ESP-KTRs were significantly higher compared with dialy-
sis patients waitlisted within the ESP (Figure 4A; P¼ 0.004).
Similarly, MCSs of ESP-KTRs were significantly higher compared
but dialysis patients waitlisted within the ESP (Figure 4A;
P< 0.001).
According to the PCS and MCS of an age-matched general
population norm [12] assessed with the SF-8, ESP-KTRs were



































































Table 1. Clinical characteristics of all ESP-KTRs and male ESP-KTRs versus female ESP-KTRs
Characteristics Total (n¼ 244) Male ESP-KTRs (n¼ 150) Female ESP-KTRs (n¼ 94) P-value
Age (years)a 67 (65–79) 67 (65–79) 68 (65–77) 0.470
Male sex, n (%) 150 (61) 148 (100) 96 (100) –
Donor age (years)a 71 (65–89) 71 (65–89) 72 (65–85) 0.925
Donor male sex, n (%) 105 (43) 70 (47) 35 (37) 0.184
Donor serum creatinine (mg/dL)a 0.88 (0.37–2.10) 0.94 (0.37–2.10) 0.97 (0.40–2.06) 0.536
KDPIa,b 97 (51–100) 97 (51–100) 97 (67–100) 0.630
Kidney donor risk index (KDRI)a,b 1.92 (1.01–3.73) 1.91 (1.01–3.73) 1.95 (1.18–2.91) 0.480
Causes of ESRD, n (%) 0.119
Glomerulonephritis 37 (15) 21 (14) 16 (17)
Diabetic nephropathy 35 (14) 25 (17) 10 (11)
Nephroangiosclersosis 38 (16) 28 (19) 10 (11)
Polycystic kidney disease 30 (12) 19 (13) 11 (12)
Uropathy 16 (7) 6 (4) 10 (11)
Other or undetermined 89 (36) 51 (34) 38 (40)
Diabetes mellitus, n (%) 82 (33) 52 (35) 30 (32) 0.679
Cold ischemia time (h:min)a 8:28 (3:04–19:35) 8:16 (3:30–17:56) 8:30 (3:04–19:35) 0.480
BMI (kg/m2)a 25.6 (16.1–40.2) 25.8 (16.1–37.0) 25.2 (17.2–40.1) 0.490
BMI >30 kg/m2, n (%) 41 (17) 24 (16) 17 (18) 0.726
Time on dialysis (months)a 52 (7–152) 54 (7–152) 52 (9–93) 0.670
4 (4)
<12 9 (4) 5 (3)
12–36 70 (29) 49 (33) 21 (22)
36–60 72 (30) 36 (24) 36 (38)
>60 93 (38) 60 (40) 33 (35)
CMV seropositivity, n (%) 160 (65) 92 (61) 68 (72) 0.097
Total HLA mismatcha 4 (0–6) 4 (0–6) 4 (0–6) 0.013
2 HLA-A MM, n (%) 84 (34) 55 (37) 29 (30) 0.407
2 HLA-B MM, n (%) 154 (63) 101 (67) 53 (56) 0.102
2 HLA-DR MM, n (%) 119 (49) 84 (56) 35 (37) 0.006
4–6 HLA MM, n (%) 180 (73) 118 (79) 62 (66) 0.036
Induction immunosuppression, n (%)
IL2-R-antagonist 237 (97) 148 (99) 89 (95) 0.111
T-cell depletion 7 (3) 2 (1) 5 (5) 0.111
Maintenance immunosuppression, n (%)
Tacrolimus/MMF/steroids 162 (66) 96 (64) 66 (70) 0.333
Cyclosporin/MMF/steroids 78 (31) 52 (35) 26 (28) 0.263
mTOR-based regime 4 (2) 2 (1) 2 (2) 0.640
Outcomes
DGF, n (%) 110 (45) 77 (51) 33 (35) 0.017
Acute cellular rejection, n (%) 82 (33) 51 (34) 31 (33) 0.890
Borderline 25 (10) 14 (9) 11 (11) 0.665
IA/IB 33 (14) 22 (15) 11 (11) 0.568
IIA/IIB/III 24 (10) 15 (10) 9 (10) 1
Cancer, n (%) 24 (10) 16 (11) 8 (8) 0.663
Causes of death, n (%) 0.329
Cardiovascular disease 22 (9) 17 (11) 5 (5)
Infection 16 (7) 8 (5) 8 (8)
Cancer 17 (7) 12 (8) 5 (5)
Other or undetermined 53 (22) 33 (22) 20 (21)
Causes of allograft loss, n (%) 0.751
Primary non-function 9 (4) 5 (3) 4 (4)
Rejection 5 (2) 2 (1) 3 (3)
Chronic allograft nephropathy 8 (3) 4 (3) 4 (4)
Infection 5 (2) 4 (3) 1 (1)
Other or undetermined 18 (7) 9 (6) 9 (10)
Death with functioning allograft, n (%) 108 (44) 70 (47) 38 (40) 0.357
PCSa 40.2 (16.8–62.5) 39.8 (23.6–60.7) 40.6 (16.8–62.5) 0.995
MCSa 48.3 (21.1–62.5) 49.1 (27.0–59.9) 48.1 (21.1–62.5) 0.977
aMedian (range).
bKDPI and KDRI calculated from donor age, donor height, donor weight, donor ethnicity, donor history of hypertension, donor history of diabetes, cause of death, donor
serum creatinine, donor hepatitis C status and donation after circulatory death. The KDRI expresses the relative risk of kidney graft failure compared with the median
kidney donor in the USA. The KDPI maps the KDRI onto a cumulative percentage scale so that a KDPI expresses a higher risk of graft failure compared with those
donors with a lower KDPI.



































































classified into those with PCS/MCS above and below average
(Table 2). No factors were identified that were associated with
impairment of physical and mental quality of life.
No differences were observed for PCS and MCS of male ver-
sus female ESP-KTRs (Figure 4B; P¼ 0.955; P¼ 0.977).
Seventy-eight of 80 ESP-KTRs (97.5%) who underwent suc-
cessful transplantation would again do so. Reasons for dialysis
patients to be waitlisted within the ESP included dependence
from dialysis (73.5%), hope for better physical capacity (51.0%),
hope for longer life expectancy (49.0%) and hope for less medi-
cation (24.5%).
DISCUSSION
With a persisting organ shortage and a soaring number of el-
derly patients awaiting kidney transplantation, an urgency to
optimize allocation of elderly kidney allografts with respect to
patient and allograft survival has arisen. In the past, short-term
outcomes of the ESP have proven to be quite successful in
achieving this goal without compromising the outcome for the
individual KTR [5, 7, 13–15]. However, despite all the applause
for the short-term ESP outcomes, burning questions arise with
respect to the long-term outcomes in this cohort. To elucidate
FIGURE 1: (A) Kaplan–Meier plot of patient survival of ESP-KTRs. ESP-KTRs show a median patient survival after kidney transplantation of 86months. (B) Kaplan–Meier
plot of patient survival between male ESP-KTRs and female ESP-KTRs. Male ESP-KTRs showed significantly inferior long-term patient survival compared with female
ESP-KTRs (P¼0.012). While no differences were observed for the first 2.5 years post-transplantation, median patient survival after kidney transplantation was
80months for male ESP-KTRs versus 131months for female ESP-KTRs. (C) Kaplan–Meier plot of patient survival between donor–recipient gender mismatch groups. No
differences are shown for patient survival between male recipients from male donors versus male recipients (Log rank: P¼ 0.390), and female recipients from female
donors versus female recipients from male donor (Log rank: P¼0.188). (D) Kaplan–Meier plot of death-censored allograft survival of ESP-KTRs. ESP-KTRs show primary
non-function in 3.7% of cases and a 5- and 10-year death-censored allograft survival of 83 and 70%. (E) Kaplan–Meier plot of death-censored allograft survival between
male ESP-KTRs and female ESP-KTRs. No differences are shown for death-censored allograft survival between male ESP-KTRs and female ESP-KTRs. (F) Kaplan–Meier
plot of death-censored allograft survival between donor–recipient gender mismatch groups. No differences are shown for death-censored allograft survival between
donor–recipient gender mismatch groups. (G) Kaplan–Meier plot of uncensored allograft survival of ESP-KTRs. ESP-KTRs show a median uncensored kidney allograft
survival of 73months. (H) Kaplan–Meier plot of uncensored allograft survival between male ESP-KTRs and female ESP-KTRs. Male ESP-KTRs show a tendency for infe-
rior uncensored allograft survival compared with female ESP-KTRs with a median of 61 versus 82months.



































































this matter, we for the first time show results of two decades of
ESP-KTRs followed at our centre.
First, T-cell-mediated rejection has been identified as the
only independent risk factor that impacts both patient survival
and death-censored kidney allograft survival among ESP-KTRs.
Principally, in the ESP-KTR cohort, avoiding T-cell-mediated re-
jection must be weighed against over immunosuppression, es-
calating the risk of severe infectious complications. Previous
studies suggest that the impact of T-cell-mediated rejection on
kidney allograft loss is aggravated among ESP-KTRs due to an
impaired ability to repair allograft injury in the elderly kidney
with reduced nephron number [16, 17]. Both immediate infec-
tious complications after T-cell-mediated rejection treatment
and associations of more impaired kidney allograft function
with cardiovascular complications may explain rejection-
related deaths in this cohort [18]. Previously, combined match-
ing for HLA-DR antigens has been proposed to be implemented
in the ESP in avoidance of increased risk of T-cell-mediated re-
jection [7, 19]. Although our data did not show HLA-DR mis-
matches impacting T-cell-mediated rejection, kidney allograft
survival or patient survival in the long-term, our data indicate
an association of HLA-DR mismatches and delayed allograft
function. Due to the small sample size of our single-centre
analysis, however, definite conclusions cannot be drawn from
our results. Therefore, new biomarkers need to be implemented
in this patient cohort to allow individualized risk stratification
to reduce T-cell-mediated rejection rates and infectious compli-
cations due to over immunosuppression.
The finding that BMI was identified as a risk factor for kidney
allograft loss remains interesting and suggests the need for ade-
quate donor nephron mass with respect to the recipient’s meta-
bolic demand. To what extent allocation of lower kidney donor
profile index (KDPI) donors to higher BMI recipients and higher
KDPI donors to lower weight recipients, to account for differen-
ces in recipient metabolic demand, may ultimately impact kid-
ney allograft survival in the elderly needs to be addressed in
upcoming studies.
Secondly, compared with the age-matched expected remain-
ing lifetime in the general German population, our data suggest
an inferior expected remaining lifetime of ESP-KTRs. Here, data
FIGURE 1: continued.



































































from the ERA-EDTA registry again support this finding [9]. In the
general population, however, women show a survival advan-
tage over men with an expected remaining lifetime of about
21.0 years compared with 17.8 years at the age of 65 years [20].
This gender gap in mortality appears to be present also after
kidney transplantation in the elderly with a median life expec-
tancy of 72 years among male ESP-KTRs and 76years among fe-
male ESP-KTRS, and a median expected remaining lifetime of
6.7 years among male ESP-KTRs compared with 10.9 years
among female ESP-KTRs. Previous studies on kidney transplan-
tation in the elderly suggest a substantial improvement of pa-
tient survival among KTRs compared with dialysis patients [21–
23]. However, the impact of chronic kidney disease, end-stage
kidney disease and reconstitution of kidney function by trans-
plantation on sex-dependent issues remains scarcely described.
Very recent data on patient survival of male versus female dial-
ysis patients suggest that the mortality advantage of women in
the general population is markedly diminished and even can-
celled among dialysis patients [9, 20, 24, 25]. This data suggest
that the gender gap in mortality is impacted at least in part by a
status of end-stage renal disease with associated complications
of uraemia and extra-renal manifestations of chronic kidney
disease. Therefore, the gender gap in mortality that is observed
in our study of ESP-KTRs suggests sex-dependent issues that re-
turn together with reconstitution of kidney function. It has been
suggested in previous studies that the explanation of the gender
gap in mortality should be based on both biological factors such
as hormones, autoimmunity and genetics, and behavioural fac-
tors [26, 27]. More importantly, it has been observed recently
that males and females basically sufller from the same diseases
leading to death but that females typically experience them
later in life [26]. This finding leads to the hypothesis that sex dif-
ferences in the onset of most common life-threatening diseases
such as cardiovascular diseases, infections and cancer are re-
versed by end-stage kidney disease and may return after kidney
FIGURE 2: (A) Change of eGFR (using the chronic kidney disease (CKD)-EPI creati-
nine equation) of ESP-KTRs with respect to baseline eGFR at 1year post-transplan-
tation. Change of eGFR showed a mean decline of 2.3 and 6.8mL/min at 5- and 10-
years post-transplantation. (B) Change of eGFR (using the CKD-EPI creatinine
equation) of male versus female ESP-KTRs with respect to baseline eGFR at 1year
post-transplantation. No differences were observed between male and female
ESP-KTRs at any time (P>0.05). KTRs who lost their kidney allograft were repre-
sented in the year they lost their kidney allograft, but not thereafter. Boxes show
the quartiles andmedians, whiskers show theminimum andmaximum values.
FIGURE 3: (A) Kaplan–Meier plot of patient survival after kidney allograft loss.
Median patient survival after kidney allograft loss was 58months. ESP-KTRs with
kidney allograft loss <12months post-transplantation showed inferior patient sur-
vival compared with ESP-KTRs with kidney allograft loss >12months post-trans-
plantation. (B) Kaplan–Meier plot of patient survival after kidney allograft loss
betweenmale ESP-KTRs and female ESP-KTRs. No differences are shown for patient
survival after kidney allograft loss betweenmale ESP-KTRs and female ESP-KTRs.



































































transplantation. At the behavioural side, the more frequent uti-
lization of healthcare services and stronger adherence to medi-
cal care among females may come more to fruition after kidney
transplantation than during dialysis treatment.
Thirdly, ESP-KTRs show a higher quality of living compared
with dialysis patients waitlisted within the ESP and even
achieve quality of living scores of the general population.
Interestingly, the improvement of quality of living seems to ap-
ply for all ESP-KTRs even in the very long-term after transplan-
tation, independent of any distinct patient characteristics. Most
dialysis patients select kidney transplantation with the hope of
improving their quality of living, and recipients of successful
transplantation consistently report a better quality of living [28,
29]. Physical well-being is significantly better among ESP-KTRs
and may be related to improvements of complications of urae-
mia that are typically not reversed fully by dialysis treatment as
anaemia, peripheral and autonomic neuropathy and metabolic
and electrolyte disorders [28–32]. More interestingly, the impact
of transplantation on mental well-being appears to be more
pronounced among ESP-KTRs. This becomes obvious with the
distribution of MCS being negatively skewed among ESP-KTRs
compared with dialysis patients. This result may be attributed
to independence from dialysis, better physical capacity and
hope for longer life expectancy.
FIGURE 4: (A) PCS and MCS between 80 ESP-KTRs and 83 patients on dialysis waitlisted within the ESP. ESP-KTRs showed significantly superior PCS and MCS compared
with patients on dialysis waitlisted within the ESP. (B) PCS and MCS between 42 male ESP-KTRs and 28 female ESP-KTRs. No differences are observed for PCS and MCS
between male ESP-KTRs and female ESP-KTRs.









averageb (n¼ 42) P-value
Age at the time of the survey (years)c 76 (69–83) 75 (67–85) 0.589 76 (68–81) 75 (67–85) 0.692
Male sex, n (%) 13 (60) 31 (62) 1 18 (60) 26 (62) 1
Donor age (years)c 70 (65–82) 71 (65–89) 0.823 71 (65–89) 81 (65–85) 0.810
Time from transplantation (months)c 71 (7–192) 69 (6–172) 0.869 68 (6–173) 72 (7–192) 0.914
Aftercare in the transplant centre, n (%) 20 (91) 43 (86) 0.712 26 (87) 37 (88) 1
Distance to transplant centre (km)c 30 (7–179) 87 (1–485) 0.290 124 (4–186) 45 (1–485) 0.533
Time to transplant centre (min)c 39 (18–160) 84 (11–269) 0.224 89 (13–151) 51 (11–269) 0.472
Time on dialysis (months)c 35 (11–91) 53 (7–152) 0.302 47 (7–105) 51 (9–142) 0.066
CAPD, n (%) 4 (18) 6 (12) 0.482 4 (13) 6 (14) 1
Causes of ESRD, n (%) 0.821 0.805
Glomerulonephritis 5 (23) 10 (20) 8 (27) 7 (17)
Diabetic nephropathy 2 (10) 5 (10) 2 (7) 5 (12)
Nephroangiosclersosis 5 (23) 7 (14) 5 (17) 7 (17)
Polycystic kidney disease 2 (10) 10 (20) 5 (17) 7 (17)
Uropathy 1 (5) 4 (8) 1 (3) 4 (11)
Other or undetermined 7 (32) 14 (28) 9 (30) 12 (29)
BMI (kg/m2)c 23 (19–32) 25 (18–36) 0.340 27 (20–36) 24 (18–32) 0.066
BMI >30 kg/m2, n (%) 3 (14) 3 (6) 0.361 4 (13) 2 (5) 0.227
Initial hospital stay (days)c 21 (7–61) 20 (9–115) 0.561 20 (11–61) 22 (7–115) 0.982
aPCS divided into ESP-KTRs with PCS above/below average according to the mean of the German population aged >70years (mean PCS¼43.3).
bMCS divided into ESP-KTRs with MCS above/below average according to the mean of the German population aged >70 years (mean MCS¼51.4).
cMedian (range).



































































Our study has several strengths. We describe the longest
follow-up at present of ESP-KTRs almost exclusively maintained
on calcineurin inhibitor, MMF and methylprednisolone and
with very high follow-up rates due to predominantly centre-
provided aftercare. We are able to show for the first time a re-
stored gender gap in mortality among KTRs who underwent
kidney transplantation in the elderly. Limitations of our analy-
sis include the single-centre approach, the relatively small sam-
ple size and the inability to provide any causality for the
observed sex difference in mortality.
To sum it up, long-term outcomes of ESP-KTRs over two dec-
ades ultimately support the effectiveness of the ESP allocation
system for the use of elderly organ donors with respect to pa-
tient survival, allograft survival and quality of living. The origi-
nal principle of decreasing CIT by neglecting HLA matching,
however, gets questioned, since HLA-DR mismatches appear to
be at least associated with a higher incidence of DGF, whereas
CIT goals of <8h were not met in the majority of the cases. The
presence of the gender gap in mortality suggests sex differences
as an important factor for treating CKD patients in the elderly. If
a change in kidney allocation such that kidneys with a longer
anticipated allograft survival are preferentially allocated to
women may improve outcomes remains questionable.
However, since very recent efforts to optimize kidney allocation
focus on estimated post-transplant survival [33], our findings
need to be evaluated in further studies.
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